Application Strategy of Toxic Chinese Materia Medica Based on the Theory of “Heterogeneous Medicinals Mutual Restriction”
10.13288/j.11-2166/r.2024.05.002
- VernacularTitle:“异类相制”理论及其指导下的有毒中药应用策略
- Author:
Xueping ZHOU
1
;
Zhe FENG
1
;
Zhichao YU
2
;
Weijue NIE
1
Author Information
1. The First Clinical Medical College， Nanjing University of Chinese medicine
2. School of Traditional Chinese Medicine， Nanjing University of Chinese Medicine
- Publication Type:Journal Article
- Keywords:
heterogeneous medicinals mutual control;
toxic Chinese materia medica;
compatibility for toxicity attenuation;
strategy of prescription
- From:
Journal of Traditional Chinese Medicine
2024;65(5):449-454
- CountryChina
- Language:Chinese
-
Abstract:
Toxic Chinese materia medica has been highly valued by its specialized and effective effects， but its safe application has become an urgent clinical problem to be solved. Compatibility for toxic attenuation is an important method for the rational clinical application of toxic Chinese materia medica as well as the promotion of its therapeutic advantages. The theory of “heterogeneous medicinals mutual restriction” elaborated in this article has been formed through long-term clinical practice and cognition， and refinement of clinical experience， which means that the nature partiality of toxic Chinese materia medica can be adjusted， and the toxicity can be suppressed through reasonable combination with herbal medicinalsof different properties， flavors， and effects. This theory covers the modes of compatibility for toxicity attenuation and the interaction relationships， like the restriction of medicinals with different properties and flavors， restriction of medicinals with different effects， and inhibiting toxins by reinforcing healthy qi. The opposite and complementary effects of various medicinals combinations are an extension of the connotations of this theory， and the principles can be explained from material basis and mechanism of action. Under the guidance of this theory， it is possible to optimize the compound prescription strategies of toxic Chinese materia medica， and provide new strategies for the clinical combinations of toxic Chinese materia medica， thereby achieving the reduction of toxicity and enhancement of effectiveness of the compound formulas.
